
MGTX Stock Forecast & Price Target
MGTX Analyst Ratings
Bulls say
MeiraGTx Holdings is a promising company due to its vertically integrated structure which gives them control over all stages of development, including manufacturing. With a strong pipeline targeting high unmet needs and partnerships such as the one with Hologen for their Parkinson's program, the company has the potential for significant growth. While there are risks, such as delays in clinical trials and competition, we believe the company's low discount rate and conservative growth rate indicate a positive long-term outlook for investors.
Bears say
MeiraGTx Holdings is a clinical-stage biotech company that is focused on developing genetic medicines for diseases with high unmet needs. Despite having in-house manufacturing capabilities, a proprietary platform, and a potential commercial product in RPGR-associated XLRP, the company's inconsistent data and regulatory uncertainties pose a significant risk to its future success and potential profitability. Additionally, the company's reliance on non-dilutive financing and its lack of revenue-generating products make it a highly speculative investment.
This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.
MGTX Analyst Forecast & Price Prediction
Start investing in MGTX
Order type
Buy in
Order amount
Est. shares
0 shares